CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Inclusion Criteria: * Male or female patients ≥ 19 years * ≥ 6 months since the last stroke * ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4) * Informed consent has been obtained Exclusion Criteria: * Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis * History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb * History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb * Fixed joint/muscle contracture * Severe atrophy * Concurrent treatment with an intrathecal baclofen * Patients who have bleeding tendency or taking anti-coagulant * Dysphagia and Breathing Difficulties * History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin * Known allergy or sensitivity to study medication or its components * Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed. * Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study. * Patient who are participating in other clinical trials at the screening * Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception. * Patients who are not eligible for this study at the discretion of the investigator.